Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 3

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 1
Chunk 3
---
Item 1. Condensed Consolidated Financial Statements

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited) 

(in thousands, except par value)June 30, 2025December 31, 2024ASSETSCurrent assets:   Cash and cash equivalents$67,669 $72,307    Short-term investments177,351 183,858    Accounts receivable, net41,288 38,376    Inventory15,489 14,114    Short-term portion of financial royalty assets, net10,276 10,025    Income taxes receivable828 4,073    Other current assets4,816 8,806    Assets held for sale (Note 2)35,228 —       Total current assets352,945 331,559 Intangible assets, net250,133 266,648 Goodwill101,541 105,250 Long-term portion of financial royalty assets, net193,556 185,024 Noncurrent derivative assets17,958 10,583 Property and equipment, net3,632 15,133 Lease right-of-use assets7,991 9,673 Other investments10,908 10,908 Deferred income taxes, net829 72 Other assets9,111 6,924       Total assets$948,604 $941,774 LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:   Accounts payable $8,584 $5,233    Accrued liabilities17,464 27,906    Income taxes payable305 1,199    Deferred revenue111 1,278    Current contingent liabilities1,465 206    Current operating lease liabilities1,089 1,266    Current finance lease liabilities24 24    Liabilities related to assets held for sale (Note 2)35,692 —       Total current liabilities64,734 37,112 Long-term deferred revenue— 2,246 Long-term contingent liabilities4,097 3,475 Long-term operating lease liabilities4,629 5,815 Deferred income taxes, net32,246 32,524 Other long-term liabilities14,369 30,163       Total liabilities120,075 111,335 Commitments